Skip to main content
Premium Trial:

Request an Annual Quote

Pharsight to Support FDA s Critical Path Initiative

NEW YORK, June 7 (GenomeWeb News) - Pharsight has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration's Center for Drug Evaluation and Research, the firms said today.

 

Under the terms of the CRADA, Pharsight will use its software to analyze, visualize, store, report, and review pharmacokinetic and pharmacodynamic data.

 

Pharsight will also provide CDER with its suite of software tools, including Pharsight Knowledgebase Server, the PKS Validation Suite, its WinNonlin Validation Suite, its Drug Model Explorer, and its Pharsight Trial Simulator. CDER will use the Pharsight tools to review clinical trial data, especially for clinical pharmacology and clinical safety reviews, and will provide feedback to Pharsight, the company said.

 

According to Robert Powell, head of pharmacometrics in FDA's Office of Clinical Pharmacology, the collaboration directly supports the FDA's Critical Path Initiative, which advocates increased use of drug-disease modeling and simulation to improve the efficiency of the drug product development process.

 

Financial details were not discussed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.